Navigation Links
Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
Date:11/19/2008

ther, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and products liability claims. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development.

In addition, sales of our products are affected by the reimbursement policies imposed by third-party payors, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of ne
'/>"/>

SOURCE Amgen
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Takedas Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed
2. Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
3. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
4. Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.
5. Millennium Presents New Data on Investigational Drugs for Novel Cancer Targets at EORTC-NCI-AACR Symposium
6. University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
7. Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkins Lymphoma
8. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
9. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
10. Raptor Pharmaceuticals Provides Update on Targeting Platforms
11. New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 2014  Amerigen Pharmaceuticals Ltd. announces that its ... received Chinese FDA (CFDA) approval and has subsequently ... the China domestic market.  ... agreement with Sinochem Jiangsu Pharmaceutical Co., Ltd., Amerigen ... approved and China CFDA certified oral solid dose ...
(Date:8/20/2014)... WORTH, Fla. , Aug. 20, 2014  Glades Drugs, ... , is proud to announce its expansion into a ... , which will feature an 8,000-square-foot office space and state ... currently accepting applications for 100 open positions for the new ... at 4560 Lantana Road will serve as the chain,s corporate ...
(Date:8/20/2014)... , Aug. 20, 2014 Trovagene, Inc. (NASDAQ: ... today that results from two clinical studies will be ... the Company,s urine-based diagnostic test for the detection of ... conference is scheduled to take place in ... 25 th . Additionally, a new U.S. patent was ...
Breaking Medicine Technology:Amerigen Pharmaceuticals Ltd. announces that its Chinese subsidiary, Suzhou Amerigen Pharmaceuticals Co. Ltd., has received Chinese FDA (CFDA) approval and has subsequently launched its generic Mecobalamin 0.5 mg Tablets into the China domestic mark 2Glades Drugs Moves to New Corporate Headquarters, 100 Open Positions 2Trovagene Provides Update on Its Urine-Based HPV Test 2Trovagene Provides Update on Its Urine-Based HPV Test 3
(Date:8/20/2014)... PA (PRWEB) August 20, 2014 A ... products from the blood did not improve survival chances ... analysis led by experts at the University of ... published online today in the journal PLOS One ... standardly used for people with sudden kidney failure, may ...
(Date:8/20/2014)... Steven Reinberg HealthDay Reporter ... disorder that dismantles a baby,s immune system is twice as ... 3 million infants says. This is the first evaluation ... treatable condition known as severe combined immunodeficiency (SCID), or "Bubble ... of this condition by the boy in the bubble, who ...
(Date:8/20/2014)... Caddis Partners LLC, has built one of the most ... in recent years, developing or acquiring 2 million square ... more than $100 million last year alone. , In ... geographic regions and a wider array of product types ... an enhanced brand identity that includes a new logo, ...
(Date:8/20/2014)... 20, 2014 Understanding the impact ... physician stakeholders networks impacting the launch of new ... Canada, and Emerging Markets. , This Flash Report ... on stakeholder management needs for the melanoma market. ... targeted therapy investigational agents that are further improving ...
(Date:8/20/2014)... MI (PRWEB) August 20, 2014 In its ... drug and alcohol treatment program that gets clients off to ... recovery they can believe in, is highlighting an important and ... be heeded by everyone who wants to understand the insidious ... are of the belief that drug abuse targets a certain ...
Breaking Medicine News(10 mins):Health News:Pitt Analysis Questions Use of Acute Hemodialysis Treatment 2Health News:'Bubble Boy' Disease May Be More Common Than Thought 2Health News:'Bubble Boy' Disease May Be More Common Than Thought 3Health News:Caddis Rebrands to Emphasize Its Growth, Expanded Capabilities 2Health News:Caddis Rebrands to Emphasize Its Growth, Expanded Capabilities 3Health News:Caddis Rebrands to Emphasize Its Growth, Expanded Capabilities 4Health News:Download HeartBeat Experts White Paper: A Stakeholder Engagement Strategy is Critical for the Evolving Melanoma Treatment Setting 2Health News:New A Forever Recovery Blog Post Reminds People that Drug Abuse Doesn’t Discriminate 2Health News:New A Forever Recovery Blog Post Reminds People that Drug Abuse Doesn’t Discriminate 3
... Systems Operations, Security and, Maintenance ... ARLINGTON, Va., Oct. 16 Vangent, ... and business process outsourcing,solutions, today announced it ... Information and Decision Support (EIDS) Infrastructure,Operations, Security ...
... risk of asthma than their urban counterparts or even ... a University of Alberta study. , Analysis of ... 12 years in the ongoing Canadian National Longitudinal Survey ... in a farming environment had a lower risk of ...
... COLUMBUS, Ga., Oct. 16 Aflac Incorporated,(NYSE: AFL ... financial,results after the market closes on October 23, 2007. ... will,webcast a conference call scheduled for 9:30 a.m. (EDT) ... and CEO Dan,Amos will discuss third quarter results and ...
... STA Travel, the world,s largest student,and youth travel organization, and ... pandemic in Africa. Through the "Good Cents,Initiative", college students across ... to compose a song, direct a video or write an,essay ... where they,will work side by side with Keep A Child ...
... "I would have never,guessed that some of the best ... come from Planned Parenthood, the largest,abortion chain in the ... Days for Life., "People in more than 80 ... about half of the vigils are being conducted outside ...
... is commonly thought that men with low IQs sexually ... deviance, new research has found the men may sexually ... previously taken. , A team of North American ... an intellectual disability and a history of sexual offence ...
Cached Medicine News:Health News:Vangent, Inc. Awarded Contract to Support Military Health System's Executive Information and Decision Support Program 2Health News:Farm kids have lower risk of asthma, study shows 2Health News:Aflac Incorporated to Release Third Quarter Results On October 23, 2007 2Health News:STA Travel and Keep a Child Alive Ask College Students to Demonstrate Their 'Good Cents' 2Health News:STA Travel and Keep a Child Alive Ask College Students to Demonstrate Their 'Good Cents' 3Health News:40 Days for Life Reaches Halfway Point; Planned Parenthood Now in Crisis Mode 2Health News:'Corrective' sex education may make sexual offenders more dangerous 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: